Moving Forward with HIV Prevention

Some exciting developments in HIV prevention were presented this past July at the IAS Conference on HIV Science. Initially, prevention of HIV transmission was only safe sex practices. Then in 2012 the drugs we know as PrEP and PEP were approved to prevent the transmission of HIV. PrEP is a prevention drug that can be taken daily the prevent transmission for people who are more likely to come into contact with HIV, like someone whose sexual partner is HIV positive. The NIAID is funding research into new ways to administer PrEP that do not require daily pills. This infographic describes the current research!

Read more about prevention efforts and advances at

Infographic titled Long-Acting Forms of HIV Prevention

For some people, long-acting forms of HIV prevention may be more desirable than a daily pill

Section titled HIV Prevention today- and in the future

Taking an oral dose of the medication Truvado once a day, every day can prevent HIV infection.

NIAID-funded researchers are developing and testing alternative HIV prevention products that could be inserted, injected, infused, or implanted from once a month (monthly)… to once a year (yearly) in people who commit to using the products on an ongoing basis.

New section titled NIAID is funding research on 4 types of long-acting HIV prevention

Intravaginal Ring (IVR): Polymer ring inserted into the vagina releases antiretroviral drug over time

Implant: Device implanted in the body releases antiretroviral drug over time

Injectable: Long-acting antiretroviral drug is injected into the body

Antibody: Antibody is infused or injected into the body

New Heading titled At What Stage Is This Research

Implant is in design and development and manufacturing and safety study stages

Ring and antibody are in manufacturing and safety study and human study stages, and injectable is in human study stage.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Spotlight On

Karam Mounzer, MD

Dr. Mounzer identified two major gaps in the care of patients with HIV/hepatitis C (HCV) co-infection, and the complexity of multidrug-resistant HIV treatment. He is involved with many clinical trials focusing on drug development and better understanding of HIV immunopathogenesis with the Wistar Institute. He is involved in teaching and mentoring.

Learn More about Spotlight On
Dr. Karam Mounzer

Dr. Mario Cruz

Dr. Mario CruzDr. Cruz is a board certified pediatrician who serves as the Medical Director for our Pediatrics and Adolescent Health Center. He has presented and/or published in the fields of community violence and domestic violence prevention, quality improvement, behavioral health, curriculum development and mentorship. In 2019 he received the Greater Philadelphia Social Innovation Award for Innovations in Healthcare.

Translate »